(Bladder Cancer) Durvalumab Receives FDA Approval
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- May 29, 2017
- Reading time: 1 minute
On May 1, 2017, UK-based AstraZeneca announced that durvalumab, an anti-PD-L1 antibody, received FDA accelerated approval for previously treated patients with advanced bladder cancer — marking the first-ever approval for this drug. The press release was titled: "AstraZeneca's Imfinzi (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer."
The approved indication covers patients with advanced or metastatic urothelial carcinoma (mUC) who have received prior platinum-based chemotherapy, as well as patients with urothelial carcinoma who received platinum-based therapy in the neoadjuvant or adjuvant setting. Notably, the approval was not restricted by PD-L1 expression level.
The basis for approval was the Phase 1/2 STUDY 1108 clinical trial, which demonstrated rapid and durable antitumor activity. Among 182 patients enrolled, the objective response rate was 17.0% (95% CI: 11.9–23.3): complete response 2.7% (n=5), partial response 14.3% (n=26), with a median duration of response not yet reached (range: 0.9+–19.9+).*1 The median time to response was 6 weeks. Of the 31 responders, 14 (45%) maintained response for ≥6 months and 5 (16%) maintained response for ≥12 months.
For those interested in PD-L1 subgroup data: the objective response rate was 26.3% (95% CI: 17.8–36.4) among 95 patients with high PD-L1 expression, 4.1% (95% CI: 0.9–11.5) among 73 patients with low or negative PD-L1 expression, and 21.4% (95% CI: 4.7–50.8) among 14 patients with indeterminate PD-L1 status.*2
*1: "Not reached" means that fewer than half of patients have died at the time of analysis, so the median survival cannot yet be calculated.
*2: PD-L1 was measured using VENTANA PD-L1 (SP263).
#BladderCancer
- Clinical trial drugs
- Immunotherapy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5